FdaApplication
NDA 212436
Identifiers
- fda_app_no: NDA212436
Properties
| Property | Value |
|---|---|
| applicant_name | PFIZER INC |
| application_type | NDA |
| approval_date | 2019-11-01 |
Revenue by product
IBRANCE
| Period | Revenue |
|---|---|
| Q2 2026 | $1.1B |
| Q1 2026 | $1.0B |
| Q3 2025 | $1.1B |
| Q2 2025 | $1.0B |
| Q1 2025 | $977.0M |
| Q3 2024 | $1.1B |
| Q2 2024 | $1.1B |
| Q1 2024 | $1.1B |
| Q4 2023 | $1.1B |
| Q3 2023 | $1.2B |
| Q2 2023 | $1.2B |
| Q1 2023 | $1.1B |
| Q4 2022 | $1.3B |
| Q3 2022 | $1.3B |
| Q2 2022 | $1.3B |
| Q1 2022 | $1.2B |
| Q4 2021 | $1.4B |
| Q3 2021 | $1.4B |
| Q2 2021 | $1.4B |
| Q1 2021 | $1.3B |
| Q4 2020 | $1.4B |
| Q3 2020 | $1.4B |
| Q2 2020 | $1.3B |
| Q1 2020 | $1.2B |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| IBRANCE | PALBOCICLIB | 125MG | TABLET;ORAL |
| IBRANCE | PALBOCICLIB | 100MG | TABLET;ORAL |
| IBRANCE | PALBOCICLIB | 75MG | TABLET;ORAL |
3 products